Gapping down
In reaction to disappointing earnings/guidance:
- N/A.
Other news:
- MNLO -58.8% (reports Phase 2 Trial of Serlopitant did not meet primary end-point)
- TLGT -7.7% (files for $50 mln mixed securities shelf offering)
Analyst comments:
- NLNK -3.6% (downgraded to Neutral at Cantor Fitzgerald)
- BEN -0.7% (downgraded to Neutral from Buy at BofA/Merrill)
- WLK -0.6% (downgraded to Neutral from Overweight at JP Morgan)
![]()